Recursion CEO Chris Gibson to step down in 2026news2025-11-05T16:20:12+00:00November 5th, 2025|Endpoints News|
Nobel laureate David Baker on Nature paper for AI antibody modelnews2025-11-05T16:00:50+00:00November 5th, 2025|Endpoints News|
Zealand CEO calls on industry to end the ‘weight loss Olympics’news2025-11-05T16:00:29+00:00November 5th, 2025|Endpoints News|
Hepta raises $6.7M to take liquid biopsy into liver diseasenews2025-11-05T16:00:04+00:00November 5th, 2025|Endpoints News|
Lilly partners with AI biologics company; Amgen ends gastric cancer studynews2025-11-05T15:27:32+00:00November 5th, 2025|Endpoints News|
Soleno’s stock drops despite rise in Prader-Willi drug salesnews2025-11-05T14:40:13+00:00November 5th, 2025|Endpoints News|
Centessa says early data for narcolepsy drug support registrational plansnews2025-11-05T12:00:41+00:00November 5th, 2025|Endpoints News|
Research institute FutureHouse debuts AI scientist Kosmos and for-profit spinoffnews2025-11-05T12:00:33+00:00November 5th, 2025|Endpoints News|
Cardio biotech Braveheart gets $185M, names Biogen CEO as its chairnews2025-11-05T11:00:13+00:00November 5th, 2025|Endpoints News|
Novo Nordisk sales miss underlines its need for Metseranews2025-11-05T10:24:34+00:00November 5th, 2025|Endpoints News|
